Search Results

An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator’s Choice of Therapy in Adult Participants with Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy MOA: PF-07248144 is a KAT6A inhibitor Key Eligibility Criteria: HR+ /HER2-negative (IHC 0/1+, IHC 2+ & ISH-) LA/met BC…

BNT324-03 A Phase III, randomized, open-label trial of BNT324 versus docetaxel with prednisone/prednisolone in metastatic castration-resistant prostate cancer MOA: BNT324 is an ADC composed of a anti-human B7-H3 IgG1 mAb covalently linked to a topo I inhibitor (P1021) via a tetrapeptide based cleavable linker. Key Eligibility Criteria: Subjects must have histological, pathological, and/or cytological confirmation…

At Maryland Oncology Hematology (MOH), our mission has always been to bring world‑class cancer care closer to home. Today, we’re proud to announce one of our most significant advancements yet: the launch of our state‑of‑the‑art Next Generation Sequencing (NGS) laboratory—an in‑house facility designed to deliver faster, more personalized, and more precise cancer insights for our…

Head and neck cancers are actually multiple kinds of cancers that develop in the throat, nose, mouth, sinuses, or larynx. These cancers have traditionally been linked to tobacco use, alcohol consumption, and the human papillomavirus (HPV). However, there may also be a link between poor oral hygiene and your risk of developing one of these…

A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR) (NVL-655-04) MOA: NVL-655 is an ALK TKI, designed for broader coverage of ALK resistance mutations, activity in the CNS, and selectivity over TRKB. Key Eligibility Criteria:…

A phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer (OPERA-02) OP-1250-302 MOA: Palazestrant (OP-1250) is an oral complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD) Key Eligibility Criteria: Confirmed ER+ (≥1%) /HER2-negative MBC and one…